Browse the evidence

TNF and NF-κB signaling pathways directly inhibit insulin signaling by phosphorylating IRS-1, thereby causing insulin resistance; neutralizing TNF or inhibiting IKKβ improves glucose homeostasis.

Chronic inflammation in fat tissue directly blocks insulin's ability to work by interfering with key signaling proteins (IRS-1). Reducing this inflammation, whether through weight loss, exercise, or potentially anti-inflammatory strategies, can restore insulin sensitivity.

Mid-day time-restricted feeding (mTRF), defined as an 8-hour eating window between 11:00 and 20:00, does not significantly improve insulin sensitivity, fasting glucose, body mass, or inflammation compared to ad libitum eating in healthy non-obese adults.

If you prefer eating later in the day (e.g., 11 AM to 7 PM), be aware that this specific mid-day TRF window may not improve insulin sensitivity, reduce body weight, or lower inflammation compared to normal eating habits in healthy, non-obese individuals. If metabolic health is your goal, shifting your eating window to end earlier (by 3 PM) may be more effective.

Obese gut microbiota reduces the capacity to metabolize ethanolamine, leading to its accumulation in the gut, which triggers a molecular cascade (ARID3a/miR-101a-3p/Zo1) that weakens intestinal barriers, causing leaky gut, systemic inflammation, and glucose metabolic dysfunction.

If you are obese or have type 2 diabetes, your gut microbiome may be failing to break down ethanolamine, leading to gut leakiness and inflammation. Supporting your gut with probiotics that specifically metabolize ethanolamine may help restore gut barrier function and improve metabolic health. Focus on dietary patterns that support a diverse microbiome.

Gut-derived GLP-1 signaling via vagal afferents regulates hepatic glucose production and postprandial glycemia, independent of direct pancreatic insulin secretion.

If you are managing blood sugar, understand that GLP-1 agonists (like Ozempic or Trulicity) do more than just trigger insulin. They send signals to your brain and liver to reduce the amount of sugar your liver releases into your blood. This neural pathway is a key reason these drugs are effective for glucose control, even if your pancreas function is declining.

Specific inflammatory pathways (JNK, IKK/NF-κB, JAK/STAT) activated by macrophage-derived cytokines (TNF-α, IL-6, IL-1β) directly impair insulin signaling by causing serine phosphorylation of IRS-1.

Understanding that inflammation directly blocks insulin action at the cellular level highlights why anti-inflammatory strategies (like weight loss) are effective for improving insulin sensitivity.

Insulin resistance (IR) fundamentally alters the association between specific lipid subclasses and clinical health markers, causing lipid profiles to diverge significantly from those seen in insulin-sensitive (IS) individuals.

If you have insulin resistance, standard lipid markers (like LDL/HDL ratios) may not predict your health risks the same way they do for healthy people. Your lipid profile's relationship with inflammation and blood sugar changes. Relying solely on standard lipid panels without assessing insulin sensitivity (e.g., fasting insulin, HOMA-IR, or SSPG) may miss critical metabolic risks.

Pro-inflammatory cytokines IL-1beta and TNF-alpha are somnogenic; their expression increases with waking activity and sleep deprivation, and they promote non-rapid-eye movement (NREM) sleep and slow-wave activity (SWA).

Prioritize sleep hygiene not just for rest, but to regulate inflammation. Chronic wakefulness or poor sleep increases pro-inflammatory cytokines like IL-1beta and TNF-alpha, which can disrupt sleep architecture and overall health. Managing inflammation through lifestyle may improve sleep, and good sleep helps manage inflammation.

The NLRP3 inflammasome is a critical mediator of sleep regulation; its activation leads to the production of IL-1beta and IL-18, which promote NREM sleep and slow-wave activity.

Understanding that sleep loss activates the NLRP3 inflammasome suggests that chronic sleep deprivation may fuel a cycle of inflammation. Breaking this cycle by improving sleep may reduce inflammasome activity.

Circadian rhythm disruption is associated with increased morbidity risk for inflammatory diseases, including cardiovascular disease, cancer, and metabolic disease.

Maintaining a regular sleep-wake cycle is crucial for long-term health, as disrupting your circadian rhythm increases the risk of inflammatory diseases like heart disease and cancer.

Exenatide (2 mg once weekly) significantly reduces alcohol cue reactivity in the ventral striatum and septal area in patients with Alcohol Use Disorder, but does not significantly reduce heavy drinking days in the general AUD population.

Exenatide, a weekly injection used for diabetes and obesity, changes how the brain responds to alcohol cues in addicted individuals, potentially reducing the 'pull' of drinking triggers. However, this neurobiological change did not automatically lead to fewer heavy drinking days for most patients in this study. It suggests that while the drug modifies reward processing, it may not be sufficient as a standalone treatment for reducing actual alcohol consumption in the general AUD population without additional behavioral support.

In obesity, elevated saturated fatty acids and proinflammatory cytokines activate JNK and IKK kinases, which phosphorylate insulin receptor substrate (IRS) on inhibitory serine residues, thereby blocking PI3K/Akt signaling and causing insulin resistance.

If you have excess body fat, your cells are likely resisting insulin due to inflammatory signaling triggered by fats and cytokines. This isn't permanent damage; it's a reversible signaling block. Reducing caloric excess and saturated fat intake can lower the metabolic stress that triggers this inflammatory kinase activity, potentially restoring insulin sensitivity.

Klotho protein functions as an anti-aging agent by inhibiting four major aging pathways (TGF-β, IGF-1, Wnt, NF-κB) and promoting antioxidant defenses, with deficiency leading to accelerated aging phenotypes and overexpression extending lifespan.

Maintaining healthy kidney function and managing metabolic health (blood sugar, blood pressure) may help preserve natural Klotho levels, which are linked to longevity. While direct Klotho supplementation is not yet a standard consumer intervention, lifestyle factors that support kidney health and reduce inflammation (like exercise and certain diets) are associated with higher Klotho expression.

The hypothalamus regulates basal metabolic rate (RMR) and adaptive thermogenesis through distinct neuronal populations and hormonal axes, with lean mass and thyroid hormone signaling being primary determinants of energy expenditure.

Focus on preserving lean muscle mass, as it is the largest driver of your resting metabolic rate. Your brain's hypothalamus regulates your baseline calorie burn through hormonal signals (like thyroid and leptin) and neural pathways. While exercise matters, your body's internal 'thermostat' sets the stage for how efficiently you burn energy at rest.

Metabolomic biomarkers, particularly Branched-Chain Amino Acids (BCAAs), aromatic amino acids, and specific lipids (ceramides, sphingomyelins), can predict the onset and progression of Metabolic Syndrome and Type 2 Diabetes before clinical symptoms appear.

Current standard blood tests may miss early metabolic dysfunction. Emerging research shows that specific amino acids and lipids rise before diabetes symptoms appear. Until these tests are routine, focus on early lifestyle changes if you have risk factors like central obesity.

A single administration of senolytic CAR T cells targeting uPAR eliminates senescent cells in aged mice, resulting in improved glucose tolerance, reduced fasting glucose, and enhanced exercise capacity.

This research suggests that targeting senescent cells via a single cellular therapy can reverse age-related metabolic decline and improve physical fitness in mice. While not yet available for human use, it highlights senolytics as a potential future intervention for longevity.

Bariatric surgery is the most effective treatment for both obesity and T2DM, offering benefits beyond weight loss by recovering islet function and normalizing gut hormones.

For severe obesity and T2DM, bariatric surgery is currently the most effective treatment, working by restoring gut hormones (GLP-1, PYY) and beta-cell function, not just by reducing stomach size. It should be considered when lifestyle changes fail, despite surgical risks.

A bimodal GLP-1/MK-801 conjugate produces synergistic weight loss and metabolic improvements in diet-induced obese rodents by targeting NMDA receptors in GLP-1-expressing brain regions, while mitigating the adverse behavioral and physiological effects of MK-801 monotherapy.

This research describes a new experimental drug that combines two mechanisms to treat obesity in animals. It works by targeting specific brain cells to reduce food intake and increase energy expenditure without the side effects of older drugs. This is not yet available for humans.

Sibutramine increases the risk of nonfatal cardiovascular events (myocardial infarction and stroke) in patients with pre-existing cardiovascular disease or type 2 diabetes with additional risk factors, leading to its contraindication in these populations.

If you have heart disease, a history of stroke, or diabetes combined with other heart risks (like high blood pressure or smoking), sibutramine is not safe for you. It increases your chance of having a heart attack or stroke. Do not use this medication if you fall into these categories; consult your doctor for safer alternatives.

Traditional weight management strategies, including lifestyle interventions and metabolic and bariatric surgery (MBS), are generally ineffective for reducing hyperphagia in patients with rare MC4R pathway diseases because they do not address the underlying pathophysiology.

For patients with rare genetic obesity (POMC, LEPR, BBS, etc.), standard diets, exercise programs, and even weight-loss surgery often fail to control the insatiable hunger (hyperphagia). This is not a failure of willpower but a failure of the treatment to address the specific brain signaling defect. Recognizing this can reduce caregiver guilt and shift focus toward seeking targeted genetic therapies.

Selective activation of Gs signaling in enteroendocrine K cells increases endogenous GIP secretion, which improves glucose tolerance in obese and diabetic mouse models.

This research suggests that therapies targeting the specific signaling pathways (Gs) in gut K cells to boost natural GIP production could be a viable strategy for managing obesity and Type 2 Diabetes, potentially offering better glucose control than current approaches that rely on external hormone administration.

Other GLP-1 receptor agonists and SGLT2 inhibitors, including semaglutide, dulaglutide, and canagliflozin, did not demonstrate a statistically significant elevation in gynecologic tumor risk compared to controls.

If you are taking other GLP-1 receptor agonists (like semaglutide or dulaglutide) or SGLT2 inhibitors (like canagliflozin or empagliflozin), this network meta-analysis did not find a statistically significant increase in gynecologic tumor risk for these agents. However, the authors note that more data is needed to confirm whether the association with tirzepatide is causal.

GLP-1 receptor agonists (GLP-1 RAs) are not cost-effective at current prices, requiring significant price reductions to meet standard willingness-to-pay thresholds.

GLP-1 RAs are clinically effective but not cost-effective at current prices. They should be used selectively (e.g., for those who cannot undergo surgery) and only if pricing aligns with their health benefits.

Peripheral GLP-1 signaling is not essential for long-term energy balance or bodyweight regulation in humans or rodents, as evidenced by normal body weight in GLP-1R knockout mice and lack of effect from peripheral antagonism.

Your body's natural production of GLP-1 in the gut does not significantly control your long-term weight. This is why lifestyle changes alone often fail to sustain weight loss, and why pharmacologic doses that strongly activate brain receptors are needed for significant weight reduction.

Hypothalamic Glp1r-expressing cells are predominantly neuronal and localized to arterial vascular beds, whereas Gipr-expressing cells are predominantly non-neuronal (oligodendrocytes and pericytes) and localized to venous vascular beds.

This research suggests that GLP-1 and GIP drugs work through different pathways in the brain. GLP-1 primarily targets neurons and arterial blood vessels, while GIP targets support cells (oligodendrocytes) and venous blood vessels. This distinct localization may explain why combining them (dual agonism) is more effective for weight loss than using GLP-1 alone.